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Background. Anemia is very common in patients with human immunodeﬁciency virus (HIV)–associated tuberculosis, and
hepcidin may be key in mediating this. We explored the relationship between blood hepcidin concentrations and anemia severity,
mycobacterial burden and mortality in patients with HIV-associated tuberculosis.
Methods. Consecutive unselected HIV-infected adults in South Africa were systematically investigated for tuberculosis. Three
groups were studied: 116 hospitalized inpatients with HIV infection and tuberculosis (hereafter, “hospitalized patients”), 58 ambu-
latory outpatients with HIV infection and newly diagnosed tuberculosis (hereafter, “ambulatory patients with tuberculosis”), and 58
ambulatory outpatients with HIV infection and without tuberculosis (hereafter, “ambulatory patients without tuberculosis”). Blood
hepcidin concentrations were determined for all patients. Vital status at 3 months was determined, and independent predictors of
mortality were identiﬁed.
Results. Median hepcidin concentrations were 38.8 ng/mL among hospitalized patients, 19.1 ng/mL among ambulatory patients
with tuberculosis, and 5.9 ng/mL among ambulatory patients without tuberculosis (P < .001). In both groups with HIV-associated
tuberculosis, hepcidin concentrations were strongly associated with greater anemia severity. Additionally, strong, graded associations
were observed between hepcidin and composite indices of mycobacterial burden and dissemination. Patients dying within 3 months
had signiﬁcantly higher hepcidin concentrations, which independently predicted mortality.
Conclusions. High hepcidin concentrations were strongly associated with disseminated disease, anemia, and poor prognosis in
patients with HIV-associated tuberculosis. Hepcidin may be a mechanistically important mediator underlying the high prevalence of
severe anemia in these patients.
Keywords. HIV; AIDS; tuberculosis; anemia; hepcidin; antimicrobial; Africa.
Tuberculosis remains the leading cause of death among people
living with human immunodeﬁciency virus (HIV) globally and
accounts for approximately 300 000 AIDS-related deaths each
year in sub-Saharan Africa [1]. Among HIV-infected patients,
low hemoglobin levels are strongly predictive for tuberculosis
[2–4], and anemia is one of the most common complications
of both disease processes [5–7]. In patients with HIV-associated
tuberculosis, anemia is strongly associated with morbidity
and risk of death [8–11]. Thus, there is a need for a better
understanding of the mechanisms underpinning anemia in
such patients so that effective interventions may be designed
and implemented. These mechanisms are likely to be multifac-
torial, although increasing evidence suggests that a majority of
patients with HIV-associated tuberculosis have anemia of
chronic disease (ACD) with or without an additional etiology
[12, 13].
Hepcidin is an acute-phase reactant peptide that is the central
regulator of iron homeostasis, and its expression is modulated
by several factors, including body iron status and hypoxia
[14]. Additionally, infections and inﬂammation may stimulate
hepcidin expression by hepatocytes, a process that is mediated
via proinﬂammatory cytokines, notably interleukin 6 (IL-6),
and signaling through the STAT-3 pathway [15, 16]. Hepcidin
drives the process of ACD by causing iron to be diverted
from the circulation and sequestered within cells of the reticu-
loendothelial system and by limiting duodenal absorption
of iron. Thus, as a consequence of inﬂammation, hepcidin
Received 25 February 2015; accepted 22 May 2015; published online 1 July 2015.
Correspondence: A. D. Kerkhoff, Department of Medicine, University of California San Fran-
cisco School of Medicine, 505 Parnassus Ave, Box 0119, San Francisco, CA 94143
(andrewkerkhoff@gmail.com).
The Journal of Infectious Diseases® 2016;213:61–70
© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of
America. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly
cited. DOI: 10.1093/infdis/jiv364
Blood Hepcidin Concentrations in HIV-Associated Tuberculosis • JID 2016:213 (1 January) • 61
restricts the availability of iron for incorporation into erythroid
progenitor cells [17].
In addition to its central role in iron regulation, hepcidin
has antimicrobial properties and appears to have an important
role in the innate immune response against Mycobacterium tu-
berculosis [15, 18–20]. While a small number of clinical studies
have demonstrated an association between elevated hepcidin
concentrations and tuberculosis [12, 21, 22], much of our
knowledge regarding the role of hepcidin in tuberculosis
has been derived from studies conducted in vitro or in animal
models. Thus, we sought to further extend this work to well-
characterized patient populations with newly diagnosed HIV-
associated tuberculosis.
We hypothesized that elevated hepcidin concentrations would
be associated with the degree of disease dissemination, as well as
with a greater prevalence and severity of anemia in patients.
Additionally, since anemia and disseminated tuberculosis are
both associated with increased mortality risk, we further exam-
ined whether hepcidin had prognostic value. In the present
study, we investigated these questions in well-characterized co-
horts of patients with HIV-associated tuberculosis and differing
disease severity (ambulatory vs hospitalized patients) in Cape
Town, South Africa.
METHODS
This study comprised hospitalized inpatients with HIV infec-
tion and newly diagnosed tuberculosis (hereafter, “hospitalized
patients”), ambulatory antiretroviral therapy (ART)–naive out-
patients with HIV infection and newly diagnosed tuberculosis
(hereafter, “ambulatory patients with tuberculosis”), and ambu-
latory ART-naive outpatients with HIV infection and without
tuberculosis (hereafter, “ambulatory patients without tubercu-
losis”). All patients were unselected and consecutively recruited
as part of two previously reported studies of tuberculosis diag-
nostic analyses [23, 24], and most resided in the township com-
munities of Cape Town, where there is a large tuberculosis
burden [25, 26]. These studies were approved by the research
ethics committees of the University of Cape Town and the Lon-
don School of Hygiene and Tropical Medicine. All patients pro-
vided written informed consent.
Hospitalized patients were drawn from among HIV-infected
patients from the same township communities who were admit-
ted to medical wards at G. F. Jooste Hospital, ≥18 years old,
without a tuberculosis diagnosis prior to admission, and sys-
tematically and thoroughly screened for tuberculosis regardless
of clinical presentation [24]. These patients were eligible for in-
clusion in the present study if they were found to have a new
microbiologically conﬁrmed diagnosis of tuberculosis, had a
frozen plasma sample available for laboratory measurements,
and had not had a blood transfusion within the 120-day period
(the approximate life span of red blood cells) prior to study
entry.
We also included ambulatory patients with and without tu-
berculosis, who would be expected to have less severe disease
than inpatients [23, 27]. Ambulatory patients were recruited
from among ART-naive, HIV-infected patients aged ≥18
years who presented for ART initiation at the Hannan Crusaid
HIV Centre and had a frozen serum sample available for labo-
ratory measurements. All were systematically screened and test-
ed microbiologically for tuberculosis regardless of clinical
presentation, to carefully deﬁne the group with and the group
without active tuberculosis. An equal number of each were in-
cluded, such that the total number of ambulatory patients
equaled the number of hospitalized patients studied. Ambulato-
ry patients with and those without tuberculosis were matched to
hospitalized patients (1:1 ratio of ambulatory to hospitalized
patients) on the basis of age (±1 year), sex, and CD4+ T-cell
count (±25 cells/µL) but not hemoglobin level.
Procedures and Data Collection
Demographic and clinical details were obtained from all partic-
ipants. Two sputum samples (spot and induced samples) were
obtained whenever possible. Urine samples were also obtained
from all patients and stored at −20°C. For hospitalized patients,
a 5.0-mL venous blood sample was inoculated into BACTEC
Myco/F Lytic culture vials (Becton Dickinson, Franklin Lakes,
New Jersey) for incubation. An additional venous blood sample
was collected from all patients for additional laboratory mea-
surements, and plasma or serum specimens were stored at
−80°C.
Full blood counts, creatinine levels, plasma viral loads, and
blood CD4+ T-cell counts at hospital admission or at the ﬁrst
clinic visit prior to ART initiation were measured by the Na-
tional Health Laboratory Service (NHLS) in Cape Town. The
results of all mycobacterial investigations and all laboratory in-
vestigations were extracted from the NHLS computerized data
system. Clinical outcomes of hospitalized patients 90 days
after study entry were determined from patient case notes, the
medical register, and electronic health record databases, where-
as clinical outcomes of ambulatory patients were determined at
follow-up visits during routine care as described previously
[28]; patients were classiﬁed as alive, dead, or lost-to-follow-up.
Laboratory Procedures
All clinical specimens for mycobacteriology were processed at
centralized accredited NHLS laboratories according to stan-
dardized protocols and quality assurance procedures as pre-
viously described [23, 27]. In brief, sputum samples were
decontaminated, pelleted by centrifugation, examined for
acid-fast bacilli by using ﬂuorescence microscopy, and tested
forM. tuberculosis by using the Xpert MTB/RIF assay (Cepheid,
Sunnyvale, California) and by liquid culture with mycobacterial
growth indicator tubes (MGIT; Becton Dickinson, Sparks,
Maryland). Any culture isolate positive for acid-fast bacilli
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was speciated to identifyM. tuberculosis complex. Urine samples
from all patients were tested using the Xpert MTB/RIF assay.
Plasma (from hospitalized patients) and serum samples
(from ambulatory patients) were tested to determine concentra-
tions of hepcidin and C-reactive protein (CRP). The concentra-
tions of hepcidin were measured using the commercially
available hepcidin 25 enzyme-linked immunosorbent assay
(ELISA; DRG Instruments, Marburg, Germany); this assay
uses a monoclonal antibody and has no known cross-reactivity
with M. tuberculosis antigens. CRP concentrations were
measured using the human CRP Quantikine ELISA (R&D Sys-
tems, Minneapolis, Minnesota). Normal ranges for hepcidin
concentrations were deﬁned as 0.6–23.3 ng/mL for males and
0.5–23.2 ng/mL for females [29]. All assays were performed in
strict accordance with the manufacturers’ instructions.
Deﬁnitions and Statistical Analysis
A new tuberculosis diagnosis among ambulatory patients with
tuberculosis was deﬁned as the detection M. tuberculosis in at
least one sputum sample by culture; among hospitalized pa-
tients, a new diagnosis was deﬁned as the detection ofM. tuber-
culosis in any clinical sample (sputum or nonrespiratory
sample) by culture or the Xpert MTB/RIF assay. Patients were
deﬁned as tuberculosis negative if all samples tested negative for
M. tuberculosis.Any patients with nontuberculousmycobacteria
isolated from their samples were excluded. Pulmonary tuber-
culosis was deﬁned as a positive sputum culture or Xpert assay
result, and extrapulmonary tuberculosis was deﬁned as a
positive culture or Xpert assay result for any nonrespiratory
sample; any patient with both pulmonary and extrapulmonary
tuberculosis was categorized as having extrapulmonary tubercu-
losis. Disseminated tuberculosis was deﬁned as the detection of
M. tuberculosis by culture or the Xpert assay in specimens
from 2 different anatomical compartments (eg, sputum, urine,
and blood).
Anemia severity was classiﬁed according to World Health
Organization criteria [30] as follows: no anemia, hemoglobin
level of ≥13.0 g/dL for men and ≥12.0 g/dL for females; mild
Table 1. Baseline Characteristics, by Study Population
Characteristic
Hospitalized Patients
(n = 116)
Ambulatory Patients With
Tuberculosis (n = 58)
Ambulatory Patients Without
Tuberculosis (n = 58)
Age, ya 34.3 (27.0–40.9) 33.9 (28.2–42.4) 33.8 (28.5–40.1)
Female sexa 77 (66.4) 38 (65.5) 36 (62.1)
ART status
Naive 56 (48.3) 100 100
Current 45 (38.8) . . . . . .
Interrupted 15 (12.9) . . . . . .
Previously treated for tuberculosis 44 (37.9) 14 (24.1) 20 (34.5)
HIV parameter
CD4+ T-cell count, cells/µLa,b 87 (33–186) 109 (42–203) 73 (32–195)
HIV load, log10 copies/mL
c 5.0 (3.2–5.7) 4.9 (4.6–5.4) 4.8 (4.2–5.2)
Hematological parameter
Hemoglobin level, g/dL 8.8 (7.5–10.8) 10.8 (8.7–11.8) 11.8 (10.5–12.8)
MCV, fLd 85 (79–89) 84 (79–89) 89 (83–92)
MCHC, g/dLd 32.9 (32.0–33.7) 33.6 (32.7–33.9) 33.4 (32.6–34.1)
WBC count, ×109 cells 7.2 (5.0–9.9) 5.8 (4.7–8.1) 4.8 (3.7–5.8)
Platelet count, ×109 cells 247 (177–334) 307 (210–419) 283 (212–347)
Hepcidin level, ng/mL 38.8 (15.7–88.8) 19.1 (9.4–53.0) 5.9 (2.8–11.1)
Kidney function
Creatinine level, µmol/Le 62 (52–86) 65 (58–82) 68 (56–77)
eGFR, mL/min/1.73 m2e 132 (95–168) 132 (91–154) 126 (109–155)
Inflammatory parameter
CRP level, mg/Ld,f 109.0 (65.0–183.9) 60.2 (20.3–174.2) 8.0 (3.4–30.8)
Data are median (interquartile range) or no. (%) of patients. “Hospitalized patients” were hospitalized inpatients with HIV infection and tuberculosis, “ambulatory patients with tuberculosis”
were ambulatory ART-naive outpatients with HIV infection and tuberculosis, and “ambulatory patients without tuberculosis” were ART-native outpatients with HIV infection but without
tuberculosis.
Abbreviations: ART, antiretroviral therapy; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; MCHC, mean corpuscular hemoglobin
concentration; MCV, mean corpuscular volume; WBC, white blood cell.
a The Kruskal–Wallis test for difference in median values of matched variables across the 3 patient population yielded the following: P = .949 for age, P = .852 for sex, and P = .883 for CD4 count.
b One result was missing for a hospitalized patient.
c Four results were missing for hospitalized patients.
d Two results were missing for hospitalized patients.
e One result was missing for an ambulatory patient with HIV infection and without tuberculosis.
f One result was missing for an ambulatory patient with HIV infection and tuberculosis.
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anemia, 11.0–12.9 g/dL for men and 11.0–11.9 g/dL for women;
moderate anemia, 8.0–10.9 g/dL for both sexes; and severe
anemia, <8.0 g/dL for both sexes. We used blood creatinine
levels to calculate an estimated glomerular ﬁltration rate
(eGFR), using the Modiﬁcation of Diet in Renal Disease
Study equation [31].
Either χ2 or Fisher exact tests, for comparison of proportions,
andWilcoxon rank sum or Kruskal–Wallis tests, for comparison
of medians, were used as appropriate. Spearman rank correla-
tion coefﬁcients were used to test the relationship between hep-
cidin concentrations and CRP concentrations. Box and whisker
plots were used to examine the relationship between hepcidin
concentrations and anemia severity, indices of mycobacterial
burden, and mortality. The corresponding medians were com-
pared using Wilcoxon rank sum or Kruskal–Wallis tests. Cox
proportional hazards regression analyses were used to deter-
mine independent predictors of mortality at 3 months. Patients
with unknown outcomes at 3 months were censored on the date
they were last seen alive in a healthcare setting. Two multivar-
iable models were constructed. The ﬁrst included covariates in
the univariable model meeting a predetermined P value cutoff
of ≤.1, as well as a priori risk factors (age, CD4+ T-cell count,
HIV load, hemoglobin level, eGFR, and CRP level). The second
model was a backward stepwise elimination model that re-
moved variables not meeting the predeﬁned P value exit crite-
rion of .1 in the multivariable model. Multivariable fractional
polynomial modeling was used to explore whether there was ev-
idence for a nonlinear relationship between hepcidin concentra-
tions and mortality. All statistical tests were 2 sided with an α
level of 0.05.
Figure 1. Box and whisker plots of hepcidin concentrations in patients with human immunodeficiency virus (HIV)–associated tuberculosis in different clinical settings,
stratified by World Health Organization (WHO) anemia severity classification. A, Hospitalized patients with HIV infection and confirmed tuberculosis (n = 116). B, Ambulatory
patients with HIV infection and confirmed tuberculosis (n = 58). C, Ambulatory patients with HIV infection but without pulmonary tuberculosis (n = 58). Bars, boxes, whiskers,
and dots indicate medians, 25th and 75th centiles, ranges, and outliers, respectively. P values were calculated by Kruskal–Wallis tests for comparison of medians.
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RESULTS
Of 139 hospitalized patients with newly diagnosed tuberculosis
who were potentially eligible, 8 did not have a plasma sample
available for additional laboratory measurements, and 15 had
received a blood transfusion within the previous 120 days.
Thus, 116 hospitalized patients (83.5%) were included. An
equal number of ambulatory ART-naive patients (n = 116)
were also included; of these, 58 had conﬁrmed tuberculosis,
and 58 did not have tuberculosis.
Baseline characteristics for each patient population are shown
in Table 1. In view of patient matching, hospitalized patients
had similar ages, sex distribution, and CD4+ T-cell counts as
ambulatory patients. Hemoglobin levels were lowest among
hospitalized patients and highest among ambulatory patients
without tuberculosis (Table 1). CRP concentrations were high-
est among hospitalized patients and nearly 2-fold higher than
those among ambulatory patients with tuberculosis (P = .028),
while CRP concentrations were much higher among ambula-
tory patients with tuberculosis, compared with ambulatory
patients without tuberculosis (7.5-fold difference; P < .001).
Among hospitalized patients, those who were ART naive tended
to have lower CD4+ T-cell counts, higher viral loads, and higher
CRP concentrations than those who were ART experienced.
However, hemoglobin levels and hepcidin concentrations did
not differ by ART status (data not shown).
Hepcidin Concentrations
The median hepcidin concentration was higher among ambula-
tory patients with tuberculosis (19.1 ng/mL), compared with
that among ambulatory patients without tuberculosis (5.9 ng/
mL; P < .001; Table 1). However, hospitalized patients had a
median hepcidin concentration of 38.8 ng/mL, which was 2.0-
fold higher than that of ambulatory patients with tuberculosis
(P < .001). Thus, hepcidin concentrations were higher among
patients with active tuberculosis, particularly those who had
more-severe clinical illness requiring admission. Hepcidin con-
centrations were highly correlated with CRP concentrations
among hospitalized patients (rho = 0.630; P < .001), ambulatory
patients with tuberculosis (rho = 0.621; P < .001), and ambula-
tory patients without tuberculosis (rho = 0.315; P = .016).
Relationship Between Hepcidin Concentrations and Anemia Severity
The relationship between hepcidin concentrations and anemia
severity is shown in Figure 1. Among hospitalized patients
(Figure 1A) and ambulatory patients with tuberculosis (Figure 1B),
direct, graded positive associations between hepcidin concen-
trations and anemia severity were observed. The highest median
hepcidin concentration was observed among those with severe
anemia, and this was 2.5-fold and 4.0-fold higher than the con-
centrations among hospitalized and ambulatory patients with
tuberculosis but without anemia, respectively. Hepcidin con-
centrations were not associated with anemia severity in ambu-
latory patients without tuberculosis (Figure 1C).
Relationship Between Hepcidin Concentrations and Mycobacterial
Burden
Among hospitalized patients, hepcidin concentrations varied
substantially according to the results of tuberculosis diagnostic
assays done on samples obtained from a range of different an-
atomical sites (Table 2). Median hepcidin concentrations were
highest in those with positive urine Xpert assay and blood cul-
ture results, and these concentrations were signiﬁcantly higher
than those among patients with negative urine Xpert assay and
blood culture results, respectively. In contrast, although numbers
were small, patients with positive cerebrospinal ﬂuid cultures and
positive pleural ﬂuid cultures had substantially lower median
hepcidin concentrations compared to those with positive blood
cultures and were within normal population ranges. Very similar
relationships between hepcidin concentrations and the results of
tuberculosis diagnostic assays were observed among ambulatory
patients with tuberculosis (Supplementary Table 1).
Next we investigated the relationship between hepcidin con-
centrations and additional indices of mycobacterial burden and
disease dissemination (Figure 2). Among hospitalized patients
and ambulatory patients with tuberculosis who had a positive
sputum culture result, there was a strong association be-
tween times to sputum positivity and hepcidin concentrations
Table 2. Relationship Between Hepcidin Concentrations and
Tuberculosis Assay Results at Different Anatomical Sites Among
Hospitalized Inpatients With Human Immunodeficiency Virus Infection
and Tuberculosis
Specimen, Test, Result
Hepcidin Level, ng/mL,
Median (IQR)
Fold-Difference
(P)
Respiratory samples
Sputum smear microscopy (n = 61)
Positive (n = 34) 50.8 (18.4–96.8) 2.2 (.201)
Negative (n = 27) 23.1 (11.0–69.7)
Sputum Xpert assay (n = 60)
Positive (n = 47) 52.2 (23.8–96.8) 2.5 (.121)
Negative (n = 13) 20.6 (12.4–53.8)
Sputum culture (n = 60)
Positive (n = 45) 52.2 (20.6–96.5) 2.3 (.074)
Negative (n = 15) 23.0 (9.9–69.7)
Nonrespiratory samples
Blood culture (n = 113)
Positive (n = 31) 61.0 (23.8–145.8) 1.8 (.029)
Negative (n = 82) 34.8 (12.4–77.3)
CSF culture (n = 17)
Positive (n = 7) 11.1 (6.0–32.8) 0.2 (.064)
Negative (n = 10) 47.2 (14.7–167.2)
Pleural fluid (n = 13)
Positive (n = 12) 16.0 (11.7–31.6) 8.4 (.109)
Negative (n = 1) 1.9
Urine Xpert assay (n = 114)
Positive (n = 74) 53.2 (21.9–142.9) 2.7 (.002)
Negative (n = 40) 19.9 (9.8–51.0)
Abbreviations: CSF, cerebrospinal fluid; IQR, interquartile range.
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(Figure 2A). Hepcidin concentrations among hospitalized
patients were much higher in patients with extrapulmonary
tuberculosis than in those with pulmonary tuberculosis
(Figure 2B). Additionally, hospitalized patients who had tuber-
culosis detected in samples obtained from ≥2 anatomical
compartments (such as sputum, urine, or blood), suggesting
disseminated tuberculosis, had much higher hepcidin concen-
trations than those with more-localized disease conﬁned to a
single anatomical site (Figure 2C). When an index of mycobac-
terial burden was constructed among ambulatory patients with
tuberculosis by combining sputum smear microscopy and urine
Xpert assay results, hepcidin concentrations directly correlated
with more-disseminated disease and were highest in patients
with both a positive sputum smear and urine Xpert assay result
(Figure 2D).
Relationship Between Hepcidin Concentrations and Mortality
Twelve hospitalized patients (10.3%) and 9 ambulatory patients
with tuberculosis (15.5%) died within 90 days of study entry; no
ambulatory patients without tuberculosis died during this
follow-up interval. Eight hospitalized patients (6.9%) and one
ambulatory patient with tuberculosis were lost to follow-up
within 90 days. The median hepcidin concentration among hos-
pitalized patients who died was 3.9-fold higher than that among
those who remained alive (144.6 ng/mL vs 37.3 ng/mL;
P < .041; Figure 3A). Similarly, the median hepcidin concentra-
tion among ambulatory patients with tuberculosis who died was
5.0-fold higher than that among those who remained alive
(75.8 ng/mL vs 15.2 ng/mL; P < .001; Figure 3B).
Multivariable Cox regression analyses were undertaken on
data from all 174 patients with tuberculosis in the combined
Figure 2. Box and whisker plots of hepcidin concentrations in patients with human immunodeficiency virus (HIV)–associated tuberculosis in different clinical settings,
stratified by indices of mycobacterial burden. A, Time to sputum culture positivity among hospitalized patients and ambulatory patients with HIV infection and confirmed
tuberculosis (n = 103). B, Tuberculosis classification among hospitalized patients with HIV infection and confirmed tuberculosis (n = 116). C, Number of unique anatomical
compartments with confirmed tuberculosis among hospitalized patients with complete sputum, blood, and urine results (n = 74). D, Composite index of mycobacterial load
combining sputum smear microscopy and urine Xpert assay results among ambulatory patients with HIV infection and confirmed tuberculosis (n = 52). Bars, boxes, whiskers,
and dots indicate medians, 25th and 75th centiles, ranges, and outliers, respectively. P values were calculated by either Wilcoxon rank sum tests or Kruskal–Wallis tests for
comparison of medians.
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hospitalized and ambulatory groups to identify whether elevat-
ed hepcidin concentrations independently predicted mortality
(Table 3). In both multivariable models, increasing hepcidin
concentrations were independently associated with greater mor-
tality risk.
DISCUSSION
Emerging evidence suggests a key role for the iron-regulator
hepcidin in the innate immune response to M. tuberculosis in-
fection [18]. In the present study, we demonstrated that hepci-
din concentrations were strongly associated with mycobacterial
burden and disseminated tuberculosis. Hepcidin concentrations
were also positively associated with greater anemia severity
among patients with tuberculosis. Finally, increased hepcidin
concentrations independently predicted poorer short-term sur-
vival among hospitalized patients.
In patients with tuberculosis, higher hepcidin concentrations
were strongly associated with more-severe anemia, and the
highest hepcidin concentrations in both hospitalized and ambu-
latory patients were among those with severe anemia (hemoglo-
bin level, <8.0 g/dL). Since hepcidin has a well-described,
central role in ACD [17], in which its expression is upregulated
predominantly by IL-6 in response to infections such as tuber-
culosis [14, 15], these results provide further evidence to suggest
that ACD is the predominant mechanism underlying anemia in
patients with HIV-associated tuberculosis [12, 13]. Further-
more, the observation that tuberculosis treatment with or with-
out ART results in normalization of hepcidin concentrations
and is associated with resolution of anemia in a majority of
patients provides further indirect evidence for ACD as the pre-
dominant mechanism of anemia in patients with tuberculosis
[12, 13, 32].
Of note, hepcidin concentrations demonstrated no associa-
tion with anemia severity among HIV-infected ambulatory
patients without tuberculosis. Anemia is common among
HIV-infected patients [5], and increased iron stores are associ-
ated with HIV replication [33, 34]. Reduction of intracellular
iron inhibits HIV transcription, and thus hepcidin may increase
transcription by inhibiting ferroportin expression and not
allowing iron efﬂux from cells [35]. Hepcidin also directly
increases HIV replication in HIV-infected macrophages and
T cells [35]. It is unclear why hepcidin was not associated
with anemia severity among ambulatory patients without tuber-
culosis in our study, as it is commonly thought that ACD is
the most important mechanism underlying anemia in HIV-
infected patients. In HIV-infected patients without tuberculosis,
a key mediator of anemia may, rather than hepcidin, be the di-
rect infection of hematopoietic progenitor cells with HIV or the
indirect effects of proinﬂammatory cytokines on hematopoietic
progenitor cells causing dysregulated erythropoiesis [36]. Addi-
tionally, the relatively small number of patients studied may
have limited the ability to detect a true association between hep-
cidin concentrations and anemia severity. The role of hepcidin
during the natural history of HIV disease without tuberculosis
or opportunistic infections and its downstream consequences
(ie, anemia) merits future study.
Hepcidin concentrations were signiﬁcantly higher among
HIV-infected patients with tuberculosis, compared to among
Figure 3. Box and whisker plots of hepcidin concentrations in patients with human immunodeficiency virus (HIV)–associated tuberculosis in different clinical settings,
stratified by vital status at 90 days. A, Hospitalized patients with HIV infection and confirmed tuberculosis (n = 116). B, Ambulatory patients with HIV infection and confirmed
tuberculosis (n = 58). Bars, boxes, whiskers, and dots indicate medians, 25th and 75th centiles, ranges, and outliers, respectively. P values were calculated by Wilcoxon rank
sum tests for comparison of medians.
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those without tuberculosis, suggesting that hepcidin concentra-
tions are related to tuberculosis and are predictive of incident
tuberculosis [21, 37]. However, hepcidin also appears to be
related to the severity of tuberculosis, as indicated by the obser-
vation of strong, graded associations between hepcidin concen-
trations and several different indices of disease dissemination/
mycobacterial load. Several mycobacterial components directly
stimulate hepcidin release from lung macrophages, alveolar ep-
ithelial cells, and dendritic cells [19, 20]. Additionally, it has pre-
viously been demonstrated that hepcidin causes growth inhibition
and structural damage to M. tuberculosis bacilli [19]. This evi-
dence collectively suggests that hepcidin may be an important
facet of the innate host response to M. tuberculosis, especially
among HIV-infected patients with highly disseminated disease.
Of further interest was the observation of greatly differing
hepcidin concentrations among the sites of tuberculosis in-
volvement. Hepcidin concentrations were highest among
those with renal tuberculosis (urine Xpert assay positive) or
mycobacteremia. Relatively low concentrations were observed
among those with conﬁrmed but isolated tuberculosis in cere-
brospinal ﬂuid or pleural ﬂuid, possibly indicating relatively
compartmentalized disease and disease with lower mycobacte-
rial load [38]. Previous studies have observed strong tuberculo-
sis-speciﬁc immune responses induced at the local site of
infection that are not reﬂected in systemic circulation [39].
Hepcidin concentrations were strongly prognostic in both
patient populations with HIV-associated tuberculosis. Among
West African HIV-infected patients, higher hepcidin concen-
trations were associated with mortality only in crude but not ad-
justed analyses [40]. Elevated hepcidin concentrations may have
prognostic value for other diseases, as well, including chronic
kidney disease and non-Hodgkin lymphoma [41, 42]. Anemia
is associated with increased mortality risk among tuberculosis
patients with and without HIV infection [10, 11] and dissem-
inated tuberculosis disease, especially in HIV-infected pa-
tients, also confers a high mortality risk [11, 43]. Our results
demonstrate that hepcidin expression is directly related to
the degree of tuberculosis dissemination and, as an undesired
Table 3. Cox Model for Predictors of Mortality Among 174 Hospitalized and Ambulatory Patients With Newly Diagnosed Human Immunodeficiency Virus
(HIV)–Associated Tuberculosis
Predictor
Unadjusted HR
(95% CI) P Value
Adjusted HR 1
(95% CI)a P
Adjusted HR 2
(95% CI)b,c,d P Value
Age in y, per unit increasee 0.99 (.95–1.04) .759 0.99 (.94–1.05) .846 . . .
Sex
Male 1 .976 . . . . . .
Female 1.01 (.41–2.51) . . . . . .
ART status
Current 1 .714 . . . . . .
Naive 1.20 (.44–3.31) . . . . . .
Interrupted 0.58 (.07–4.98) . . . . . .
Patient typee
Hospitalized inpatient 1 .332 1 .020 1 .022
Ambulatory outpatient 1.54 (.65–3.67) 4.23 (1.30–13.81) 3.27 (1.20–8.93)
Disseminated tuberculosise
No 1 <.001 1 .426 . . .
Yes 3.30 (1.19–9.17) 1.65 (.46–1.01) . . .
HIV parameters
CD4+ T-cell count in cells/µL, per 10-unit decreasee 1.11 (1.03–1.20) .003 1.12 (1.30–13.81) .006 1.13 (1.04–1.23) <.001
HIV load in copies/mL, per unit increasee 1.09 (.79–1.51) .583 0.69 (.47–1.03) .074 0.69 (.47–1.02) .073
Hematological parameter
Hemoglobin level in g/dL, per unit decreasee 1.27 (1.03–1.55) .017 0.93 (.69–1.25) .630 . . .
Hepcidin level in ng/mL, per 10-unit increasee 1.09 (1.05–1.14) <.001 1.08 (1.01–1.16) .029 1.11 (1.05–1.17) <.001
Kidney functione
eGFR in mL/min/1.73 m2, per 10-unit decreasee 1.05 (.96–1.15) .309 1.01 (.91–1.11) .877 . . .
Inflammatory marker
CRP level in mg/L, per 10-unit increasee 1.05 (1.02–1.09) .010 1.02 (.97–1.07) .478 . . .
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HR, hazard ratio.
a There were 155 patients who had complete results and were included in the final model.
b There was no evidence of collinearity among any of the variables included in the final model.
c There was no evidence of interaction between hepcidin and any variables included in the final model. No evidence was found to suggest a nonlinear relationship between hepcidin
concentrations and mortality.
d There were 173 patients who had complete results and were included in the final stepwise backward elimination model.
e A priori variables.
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consequence of hepcidin’s role in the host response to dissem-
inated mycobacterial disease, may result in ACD. Therefore,
both hepcidin (upstream) and anemia (downstream) have
prognostic value in HIV-associated tuberculosis, as they are
both related to greater tuberculosis severity. It is worth noting,
however, that in this study, anemia was not an independent
predictor of mortality after adjustment for hepcidin and
other possible confounding variables, suggesting that hepcidin
is more predictive than hemoglobin levels of mortality in this
patient population.
A major strength of this study was that relationships with hep-
cidin concentrations were explored in three well-characterized
patient groups. This allowed us to compare ﬁndings in patients
from different clinical settings (inpatient and outpatient),
which were largely in agreement and improves the generalizabil-
ity of our ﬁndings. Furthermore, because of a very thorough tu-
berculosis screening strategy in the parent studies, we were able to
explore the relationship between hepcidin and conﬁrmed tuber-
culosis in several different anatomical compartments. A limita-
tion is that no single measure of mycobacterial burden exists,
although microscopy, Xpert assay, and culture each have well-
described lower limits of detection that are strongly correlated
with known concentrations of mycobacteria [44]. As hepcidin
and CRP levels were measured in plasma samples for hospital-
ized patients, this may have resulted in a slight underestimation
of concentrations, compared with values for ambulatory patients,
for whom serum specimens were measured (<10% difference)
[45]; however, the majority of analyses and the key ﬁndings
were derived from within-group analyses and could therefore
not have not been affected by this. Given the observational design
of this study, we were only able to report associations with hep-
cidin concentrations, but our results are consistent with in vitro
studies and those conducted using animal models.
Hepcidin concentrations were strongly and positively associat-
ed with mycobacterial burden, suggesting that hepcidin may have
a role in the host response to disseminated tuberculosis in HIV-
infected patients. As hepcidin was also strongly correlated with
more severe anemia, this implies that anemia may be a common
and unfavorable consequence of this response. Therefore, hepci-
din may be a mechanistically important mediator underlying the
high prevalence of severe anemia among patients with HIV-
associated tuberculosis, especially those with disseminated disease.
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